BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/9/2024 12:51:13 PM | Browse: 114 | Download: 992
 |
Received |
|
2024-06-05 10:55 |
|
Peer-Review Started |
|
2024-06-05 10:55 |
|
First Decision by Editorial Office Director |
|
2024-06-25 10:55 |
|
Return for Revision |
|
2024-06-25 10:55 |
|
Revised |
|
2024-07-08 07:42 |
|
Publication Fee Transferred |
|
2024-07-22 12:34 |
|
Second Decision by Editor |
|
2024-07-16 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-16 06:00 |
|
Articles in Press |
|
2024-07-16 06:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-31 01:56 |
|
Publish the Manuscript Online |
|
2024-08-09 12:51 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ling-Xiao Xu, Jia-Jia Yuan, Ran Xue and Jun Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun Zhou, MD, Chief Doctor, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. joelbmu@126.com |
| Key Words |
Nab-paclitaxel; Capecitabine; Biliary tract cancer; Objective response rate; Phase II clinical trial |
| Core Tip |
Our study investigates the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic biliary tract cancers (BTCs). Through an open-label, non-randomized, double-center, phase II clinical trial, we enrolled systemic therapy-naive patients. Our findings demonstrate that nab-paclitaxel plus capecitabine demonstrates both acceptable efficacy and safety in patients with advanced and metastatic BTCs. This regimen shows promise as a potential novel treatment option for this patient population and warrants further validation in future trials. |
| Publish Date |
2024-08-09 12:51 |
| Citation |
Xu LX, Yuan JJ, Xue R, Zhou J. Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. World J Gastroenterol 2024; 30(30): 3564-3573 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i30/3564.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i30.3564 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
